AbyD-3263

N/A

Report date: 2025/03/14 20:00:48

Base Information

Drug NameAbyD-3263

Drug Alias Nameanti-PDGFbeta mAb (Pfizer)

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody

Mechanisms of ActionPlatelet-derived growth factor receptor beta inhibitors

TargetsPlatelet-derived growth factor receptor beta

Therapy Area/IndicationsLiver Cirrhosis

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesPfizer Inc

China Registration ClassN/A

Active CompaniesN/A

Inactive CompaniesPfizer Inc

Active IndicationsN/A

Inactive IndicationsLiver Cirrhosis

ATC CodeN/A